RxDoctor Payments DataLook up a doctor →

Gregory Swor, MD

Urogynecology and Reconstructive Pelvic Surgery · Sarasota, FLNPI 1447439245

Payments from drug & device makers

$1,230,624in general payments, 2019–2025

Across 667 payments — averaging $1845.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$321K
  • Bayer$169K
  • Abbott$161K
  • Mylan Inc.$129K
  • Sumitomo Pharma America, Inc.$93K
  • Teva Pharmaceuticals USA, Inc.$79K
  • plus $280K from 51 others

What the payments were for

  • Consulting fees$2,45037%
  • Speaking & faculty fees$3005%
  • Food & beverage$3,75157%
  • Education$731%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,230,624 in reported general payments places this provider in the 95th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.

See all urogynecology and reconstructive pelvic surgery providers in Florida

Medicare billing

Part B allowed, 2024
$168,722
Medicare patients
583
Services billed
1,915

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol214$12,136
PremarinEstrogens, Conjugated16$7,543
Estradiol (Twice Weekly)Estradiol71$6,663
ProgesteroneProgesterone, Micronized154$5,189
VagifemEstradiol12$2,961
DottiEstradiol15$2,720
Estradiol (Once Weekly)Estradiol37$2,402
Metronidazole17$720
ValacyclovirValacyclovir Hcl27$569
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst22$242
Clobetasol Propionate11$114
Medroxyprogesterone Acetate13$106
Fluconazole29$100
Naproxen18$52
Tramadol Hcl13$33

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$178$7,54316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.

Other urogynecology and reconstructive pelvic surgery in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →